Long-term renal survival of paediatric patients with lupus nephritis

被引:27
作者
Demir, Selcan [1 ]
Gulhan, Bora [2 ]
Ozen, Seza [1 ]
Celegen, Kubra [2 ]
Batu, Ezgi Deniz [1 ]
Tas, Nesrin [2 ]
Orhan, Diclehan [3 ]
Bilginer, Yelda [1 ]
Duzova, Ali [2 ]
Ozaltin, Fatih [2 ,4 ]
Topaloglu, Rezan [2 ]
机构
[1] Hacettepe Univ, Dept Pediat, Div Rheumatol, Fac Med, Ankara, Turkey
[2] Hacettepe Univ, Dept Pediat, Div Nephrol, Fac Med, Ankara, Turkey
[3] Hacettepe Univ, Dept Pediat & Perinatal Pathol Res, Fac Med, Ankara, Turkey
[4] Hacettepe Univ, Nephrogenet Lab, Fac Med, Ankara, Turkey
关键词
childhood-onset systemic lupus erythematosus; cyclophosphamide; lupus nephritis; mycophenolate mofetil; renal outcome; MORTALITY; ERYTHEMATOSUS; CHILDHOOD; OUTCOMES; CHILDREN; THERAPY; COHORT; CLASSIFICATION; GUIDELINES; MANAGEMENT;
D O I
10.1093/ndt/gfab152
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background Childhood-onset systemic lupus erythematosus (SLE) is more severe than adult-onset disease, including more frequent kidney involvement. This study aimed to investigate baseline clinical features, treatment modalities and short- and long-term renal outcomes of paediatric patients with lupus nephritis (LN). Materials and methods This study enrolled 53 LN patients out of 102 childhood-onset SLE patients followed at Hacettepe University between 2000 and 2020. The demographic and clinical data were reviewed retrospectively from the medical charts and electronic records. All SLE patients with renal involvement underwent renal biopsy either at the time of diagnosis or during follow-up. Results The median age at onset of SLE was 13.3 years [interquartile range (IQR) 10.4-15.8]. The median follow-up duration was 43.1 months (IQR 24.3-69.3). Of the 102 SLE patients, 53 (52%) had LN. The most frequent histopathological class was Class IV LN (54.7%), followed by Class III (22.6%). The proportion of patients who achieved either complete or partial remission was 77.3% and 73% at 6 and 12 months, respectively. In the overall LN cohort, 5- and 10-year renal survival rates were 92% and 85.7%, respectively. The remission rate at Month 6 was significantly higher in mycophenolate mofetil (MMF)- and cyclophosphamide (CYC)-treated groups than other combination therapies (P = 0.02). Although no difference was found between the CYC and MMF response rates (P = 0.57) in proliferative LN (Classes III and IV), the majority of Class IV patients (79%) received CYC as induction therapy. There was no difference between the response rates in any treatment regimens at Month 12 (P = 0.56). In the multivariate analysis, male gender, requiring dialysis at the time of LN diagnosis and failure to achieve remission at 6 and 12 months were found to be associated with poor renal outcome. Conclusions Our study demonstrated that male gender, failure to achieve remission at 6 and 12 months and requiring dialysis at the time of diagnosis were the best predictors of poor renal outcome. Therefore appropriate and aggressive management of paediatric LN is essential to achieve and maintain remission.
引用
收藏
页码:1069 / 1077
页数:9
相关论文
共 40 条
[1]   Prophylaxis of the antiphospholipid syndrome:: a consensus report [J].
Alarcón-Segovia, D ;
Boffa, MC ;
Branch, W ;
Cervera, R ;
Gharavi, A ;
Khamashta, M ;
Shoenfeld, Y ;
Wilson, W ;
Roubey, R .
LUPUS, 2003, 12 (07) :499-503
[2]   Good outcomes with mycophenolate-cyclosporine-based induction protocol in children with severe proliferative lupus nephritis [J].
Aragon, E. ;
Chan, Y. H. ;
Ng, K. H. ;
Lau, Y. W. ;
Tan, P. H. ;
Yap, H. K. .
LUPUS, 2010, 19 (08) :965-973
[3]   Long-term renal outcome and complications in South Africans with proliferative lupus nephritis [J].
Ayodele, Olugbenga E. ;
Okpechi, Ikechi G. ;
Swanepoel, Charles R. .
INTERNATIONAL UROLOGY AND NEPHROLOGY, 2013, 45 (05) :1289-1300
[4]   Can morbidity and mortality of SLE be improved? [J].
Bongu, A ;
Chang, E ;
Ramsey-Goldman, R .
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2002, 16 (02) :313-332
[5]   Lupus nephritis: A critical review [J].
Borchers, Andrea T. ;
Leibushor, Naama ;
Naguwa, Stanley M. ;
Cheema, Gurtej S. ;
Shoenfeld, Yehuda ;
Gershwin, M. Eric .
AUTOIMMUNITY REVIEWS, 2012, 12 (02) :174-194
[6]  
Cameron JS, 1999, J AM SOC NEPHROL, V10, P413
[7]   LUPUS NEPHRITIS IN CHILDHOOD AND ADOLESCENCE [J].
CAMERON, JS .
PEDIATRIC NEPHROLOGY, 1994, 8 (02) :230-249
[8]   Morbidity and mortality in systemic lupus erythematosus during a 10-year period -: A comparison of early and late manifestations in a cohort of 1,000 patients [J].
Cervera, R ;
Khamashta, MA ;
Font, J ;
Sebastiani, GD ;
Gil, A ;
Lavilla, P ;
Mejía, JC ;
Aydintug, AC ;
Chwalinska-Sadowska, H ;
de Ramón, E ;
Fernández-Nebro, A ;
Galeazzi, M ;
Valen, M ;
Mathieu, A ;
Houssiau, FD ;
Caro, N ;
Alba, P ;
Ramos-Casals, M ;
Ingelmo, M ;
Hughes, GRV .
MEDICINE, 2003, 82 (05) :299-308
[9]   Value of a complete or partial remission in severe lupus nephritis [J].
Chen, Yiann E. ;
Korbet, Stephen M. ;
Katz, Robert S. ;
Schwartz, Melvin M. ;
Lewis, Edmund J. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (01) :46-53
[10]   Long-Term Mortality and Renal Outcome in a Cohort of 100 Patients With Lupus Nephritis [J].
Faurschou, Mikkel ;
Dreyer, Lene ;
Kamper, Anne-Lise ;
Starklint, Henrik ;
Jacobsen, Soren .
ARTHRITIS CARE & RESEARCH, 2010, 62 (06) :873-880